Researcher
Chris Marine
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
Affiliations
- Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Marine Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Member
From1 Oct 2013 → Today - Department of Human Genetics (Department)
Member
From1 Oct 2009 → 31 Dec 2016
Projects
1 - 10 of 63
- Understanding and targeting melanoma mesenchymal-like cells to improve response to immunotherapyFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Deciphering molecular mechanisms and intercellular communication networks underlying the emergence of the metastasis-initiating melanoma cellFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Spatio-temporal dissection of inter-cellular melanoma communication networks that contribute to resistance to immunotherapy.From1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Empowering precision medicine in melanoma: Exploring the potential of an implantable microdevice for large-scale drug screening in vivoFrom12 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Microfluidic tools to study single-cell responses and cell-cell communication in cancer applicationsFrom15 Aug 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Identification of universal biomarkers of metastatic melanoma in CTCsFrom30 May 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Detection and prevention of early metastatic dissemination of melanomaFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Dissecting the heterotypic cell communication networks at the perivascular niche to detect andintercept the early metastatic processFrom1 Jan 2023 → TodayFunding: BOF - iBOF
- Dissecting the cellular and molecular interaction networks that promote melanoma stemness at the perivascular niche.From1 Oct 2022 → TodayFunding: FWO senior postdoctoral fellowship
- Circulating tumor cells as a target of anti-metastatic treatment in melanoma.From1 Sep 2022 → TodayFunding: FWO Strategic Basic Research Grant
Publications
1 - 10 of 153
- Cancer Evolution: A Multifaceted Affair.(2024)
Authors: Chris Marine
Pages: 36 - 48 - A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma(2024)
Authors: Dennis Pedri, Ewout Landeloos, Yannick Van Herck, Katy Vandereyken, Thierry Voet, Wim Annaert, Diether Lambrechts, Veerle Boecxstaens, Joost van den Oord, Francesca Bosisio, et al.
- Perivascular niches: critical hubs in cancer evolution(2023)
Authors: Ada Nowosad, Chris Marine, Panagiotis Karras
Pages: 897 - 910 - Development of novel methods for single-cell whole-genome amplification to study cancer heterogeneity.(2023)
Authors: Koen Theunis, Thierry Voet, Chris Marine
- The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells (vol 21, pg 525, 2007)(2023)
Authors: Chris Marine
Pages: 861 - 861 - The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity(2023)
Authors: Oliver Bechter, Chris Marine
Pages: 1207 - + - Melanoma-intrinsic NR2F6 activity regulates antitumor immunity(2023)
Authors: Chris Marine
- CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours(2023)
Authors: Francesca Bosisio, Oliver Bechter, Chris Marine
Pages: 1033 - + - Apoptotic cell death in disease-Current understanding of the NCCD 2023(2023)
Authors: Patrizia Agostinis, Bart De Strooper, Abhishek Garg, Chris Marine
Pages: 1097 - 1154 - Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy(2023)
Authors: Ali Talebi, Vincent de Laat, Xander Spotbeen, Jonas Dehairs, Ginevra Doglioni, David Nittner, Tania Roskams, Patrizia Agostinis, Oliver Bechter, Veerle Boecxstaens, et al.
Patents
1 - 10 of 10
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Direct and selective inhibition of mdm4 for treatment of cancer (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Inhibition of a lncrna for treatment of melanoma (Inventor)